Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
Dosing is underway in a Phase 3 clinical trial evaluating Dermira's (NASDAQ: DERM ) lebrikizumab, an IL-13 inhibitor, in patients at least 12 years old with moderate-to-severe atopic dermatitis (AD). More news on: Dermira, Inc., Almirall, S.A., Healthcare stocks news, Stocks on the move...
Almirall, S.A. (LBTSF) Half Year 2019 Earnings Conference Call July 29 2019, 4:00 AM ET Company Participants Pablo Divasson del Fraile – Head of Investor Relations Peter Guenter – Chief Executive Officer David Nieto – Executive Vice President and Chief Financ...
The following slide deck was published by Almirall, S.A. in conjunction with their 2019 Q2 earnings Read more ...
Almirall, S.A. ( OTC:LBTSF ): 1H net income of €62M More news on: Almirall, S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
Almirall, S.A (LBTSF) Q1 2019 Earnings Conference Call May 13, 2019 4:00 AM ET Company Participants Pablo Divasson del Fraile – Head of Investor Relations Peter Guenter – Chief Executive Officer David Nieto – Executive Vice President and Chief Financial Offic...
The following slide deck was published by Almirall, S.A. in conjunction with their 2019 Q1 earnings Read more ...
Almirall, S.A. ( OTC:LBTSF ): Q1 Normalized Net Income of €32.6M More news on: Almirall, S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
In October 2018, Paratek Pharmaceuticals ( PRTK ) received FDA approvals for its two main products - SEYSARA and NUZYRA. The company also entered into an exclusive licensing agreement with Almirall ( LBTSF ) for the development and commercialization rights of SEYSARA, which was launched in the...
Almirall SA (LBTSF) Full Year 2018 Earnings Conference Call February 25, 2019, 4:00 AM ET Company Participants Pablo Divasson del Fraile – Head of Investor Relations Peter Guenter – Chief Executive Officer Ron Menezes – GM of Almirall U.S. David Nieto ...
The following slide deck was published by Almirall SA in conjunction with their 2018 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Strong growth trajectory maintained with Net Sales increase of 6.7% to a total of €497.2 MM, EBITDA of €104.5 MM (+3.2% YoY) driven by increased overall sales and strong performance of biologics portfolio Biologics continue to be key growth engines for Almirall: Ebglyss ...
Lebrikizumab is recommended by NICE for the use in moderate to severe Atopic Dermatitis in patients 12 years and over when their condition has not responded to at least 1 systemic immunosuppressant, or when these treatments are not suitable Following approval of the European Commission (Octob...
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...